Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

A phase I study of the bispecific antibody MDX-H210 in combination with granulocyte colony-stimulating factor (G-CSF) was performed in stage IV breast carcinoma patients, overexpressing HER-2/neu. MDX-H210, constructed by crosslinking antigen binding fragments (F(ab′) fragments) of monoclonal antibo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Repp, R, van Ojik, H H, Valerius, T, Groenewegen, G, Wieland, G, Oetzel, C, Stockmeyer, B, Becker, W, Eisenhut, M, Steininger, H, Deo, Y M, Blijham, G H, Kalden, J R, van de Winkel, J G J, Gramatzki, M
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2003
Soggetti:
Clinical
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2395280/
https://ncbi.nlm.nih.gov/pubmed/14676800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601367
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi